BACKGROUND: Prolactinomas invading the skull base are rare, and could easily be confused with skull base tumors of nonpituitary origin. CASE DESCRIPTION: We report a series of 4 cases of giant prolactinomas invading the skull base and presenting with atypical symptoms. Case 1 presented with a short history of headache and nasal obstruction. Case 2 presented with progressive hypoacusia, dizziness, and ophthalmoplegia. In Case 3, the patient developed rapid progressive visual failure and psychiatric symptoms. Case 4 presented with a 1-year history of headache and retrorbital pain. The diagnosis of prolactinoma was made on the basis of tumor immunohistochemistry and/or high plasma prolactin levels (range from 650-6,500 ng/mL). Medical treatment with the dopamine agonist cabergoline was given; it was effective in normalizing prolactin levels and inducing tumor shrinkage. CONCLUSION: Prolactin levels should be measured in all large skull base tumors involving the pituitary region before any surgery or inappropriate radiotherapy is performed.
BACKGROUND:Prolactinomas invading the skull base are rare, and could easily be confused with skull base tumors of nonpituitary origin. CASE DESCRIPTION: We report a series of 4 cases of giant prolactinomas invading the skull base and presenting with atypical symptoms. Case 1 presented with a short history of headache and nasal obstruction. Case 2 presented with progressive hypoacusia, dizziness, and ophthalmoplegia. In Case 3, the patient developed rapid progressive visual failure and psychiatric symptoms. Case 4 presented with a 1-year history of headache and retrorbital pain. The diagnosis of prolactinoma was made on the basis of tumor immunohistochemistry and/or high plasma prolactin levels (range from 650-6,500 ng/mL). Medical treatment with the dopamine agonist cabergoline was given; it was effective in normalizing prolactin levels and inducing tumor shrinkage. CONCLUSION:Prolactin levels should be measured in all large skull base tumors involving the pituitary region before any surgery or inappropriate radiotherapy is performed.
Authors: Ricardo J Komotar; Robert M Starke; Daniel M S Raper; Vijay K Anand; Theodore H Schwartz Journal: Pituitary Date: 2012-06 Impact factor: 4.107
Authors: Paula Andujar-Plata; Rocio Villar-Taibo; Maria Dolores Ballesteros-Pomar; Alfonso Vidal-Casariego; Begoña Pérez-Corral; Jose Manuel Cabezas-Agrícola; Paula Álvarez-Vázquez; Ramón Serramito; Ignacio Bernabeu Journal: Endocrine Date: 2016-10-04 Impact factor: 3.633
Authors: Aleksandra Sliwinska; Fatima Jalil; Lori De La Portilla; Michael Baldwin; Joseph Lorenzo; Ketan R Bulsara; Faryal S Mirza Journal: J Endocr Soc Date: 2021-04-14